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MaBACKGROUND Coronary artery spasm contributes to the pathogenesis of variant angina and ischemic heart disease
and may play a role in the progression of atherosclerosis. It is unclear whether the location of spasm is related to
outcome.
OBJECTIVES This study compared the clinical features and prognosis of patients with coronary spasm at the site of
signiﬁcant atherosclerotic stenosis with patients with spasm at sites without stenosis or nonsigniﬁcant stenosis.
METHODS This was a retrospective, observational study of 1,877 consecutive patients with typical or atypical angina-
like chest pain undergoing acetylcholine (ACh)-provocation testing. A total of 1,760 patients were eligible for analysis.
ACh-provoked coronary spasm and signiﬁcant organic stenosis were observed in 873 and 358 patients, respectively.
RESULTS In patients with signiﬁcant atherosclerotic stenosis, ACh-positive patients (n ¼ 233) were younger and
without diabetes mellitus compared with nonspasm patients (n ¼ 125). In patients without organic stenosis, ACh-positive
patients (n ¼ 640) were older, had dyslipidemia, and were more likely to have a family history of ischemic heart disease
than nonspasm patients (n ¼ 762). Multiple logistic regression analysis identiﬁed ST-segment elevation during anginal
attacks, organic stenosis of the left anterior descending artery, and multivessel spasm as correlates of spasm at sites of
signiﬁcant organic stenosis (n ¼ 192). Multivariate analysis identiﬁed ACh-provoked spasm at the site of signiﬁcant
stenosis and use of nitrates as the 2 prognostic factors for major adverse cardiac events.
CONCLUSIONS The clinical features and prognosis of patients with ACh-provoked coronary spasm were different when
it occurred at the site of signiﬁcant atherosclerotic stenosis compared with patients with spasm elsewhere. Both spasm at
the site of signiﬁcant organic stenosis and nitrate use were signiﬁcant predictors of major adverse cardiac events.
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ABBR EV I A T I ON S
AND ACRONYMS
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CI = conﬁdence interval
HR = hazard ratio
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LAD = left anterior descending
MACE = major adverse cardiac
event(s)
OR = odds ratio
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1106of organic coronary artery stenosis is a signif-
icant risk factor for cardiovascular events in
patients with vasospastic angina (VSA)
(9,10). However, it is not clear whether the
clinical features and long-term prognosis of
VSA patients with coronary spasm at the
site of signiﬁcant organic stenosis are
different from those of patients with coro-
nary spasm occurring at other sites or pa-
tients without organic stenosis.
The purpose of the present study was
to compare the clinical features, predictive
factors, and prognosis of patients with coro-
nary spasm based on the presence or absence
of organic stenosis.SEE PAGE 1116METHODS
Between January 1991 and December 2010, all 1,877
consecutive Japanese patients who had typical
or atypical angina-like chest pain and underwent
acetylcholine (ACh)-provocation testing at Kuma-
moto University Hospital were enrolled in the present
study. Of these patients, 117 were excluded, leaving
1,760 patients for analysis (Figure 1). The ACh-
provocation test was performed as described previ-
ously in the Guidelines for Diagnosis and Treatment
of Patients with Vasospastic Angina from the Japa-
nese Circulation Society (11).
We deﬁned coronary spasm as total or subtotal
obstruction within the borders of 1 isolated coronary
segment or severe diffuse vasoconstriction observed
in $2 adjacent coronary segments (i.e., diffuse spasm)
of epicardial coronary arteries associated with tran-
sient myocardial ischemia as evidenced by ischemic
ST-segment change on the electrocardiogram, as
described previously (12). Multivessel spasm was
deﬁned as ACh-provoked spasm of more than 2 major
epicardial arteries.
The study protocol was approved by the Human
Ethics Review Committee of Kumamoto University
and a signed consent form was obtained from each
subject.
DATA COLLECTION AND FOLLOW-UP. In this retro-
spective study, patient demographic and clinical data
were collected from the medical records. The risk
factors for CAD were deﬁned previously (12). Patients
with a positive ACh-provocation test were divided
into 2 groups based on the comorbidity of signiﬁcant
atherosclerotic stenosis (or “organic stenosis”),
assessed as $75% stenosis of the right, left anterior
descending (LAD), or left circumﬂex coronary arteryand the major branches, or $50% stenosis of the left
main trunk by coronary angiography. The type of
coronary spasm with organic stenosis was classiﬁed
based on the positional relation of ACh-provoked
coronary spasm to signiﬁcant stenosis. Spasm at the
site of organic stenosis was deﬁned as coronary
spasm observed at the site of signiﬁcant atheroscle-
rotic stenosis. However, we deﬁned spasm at sites
other than the site of organic stenosis as coronary
spasm at alternative sites of either mild or no organic
stenosis in patients with signiﬁcant stenosis (but not
at the site of signiﬁcant atherosclerotic stenosis).
Follow-up data of patients of the ACh-positive
group were obtained directly from the patients, their
families, or their family physicians, in addition to the
information available in the medical records. Major
adverse cardiac events (MACE) were assessed by phy-
sicians masked to the details in the medical records.
The primary endpoint was MACE, including cardiac
death, hospitalization for acute myocardial infarction
(AMI), and unstable angina pectoris during the follow-
up period that began from the date of the VSA diag-
nosis to the date of ﬁrst event or until December 2012.
The secondary endpoint was all-cause mortality. Car-
diac death was deﬁned as sudden death or death
associated with AMI, which itself was deﬁned by the
presence of severe chest pain lasting >30 min associ-
ated with ST-segment changes and elevated cardiac
enzyme levels. Unstable angina pectoris represented
recurrence or worsening of chest discomfort or pain
associated with ischemic electrocardiogram changes.
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean  SD, and categorical variables as
frequencies and percentages. Group comparisonswere
analyzed by the unpaired Student t test for continuous
variables, the chi-square test or Fisher exact test for
categorical variables, and the log-rank test for MACE-
free survival curves. Age, sex, and relationship be-
tween the results of ACh-provocation test and other
signiﬁcant parameters in simple logistic analysis were
entered intomultiple logistic regression analysis using
the forced entry method. Cox proportional hazards
regression was used to compute hazard ratios (HRs)
and 95% conﬁdence intervals (CI) as estimates for the
endpoint. The HRs were adjusted for clinical charac-
teristics, angiographic ﬁndings, and medication ac-
cording to the univariate analysis for the endpoint. All
variables with p < 0.05 on the univariate analysis and
well-known predictive factors were entered into the
stepwise backward selection method in the multivar-
iatemodel. In the Cox proportional hazards regression,
we evaluated HRs and 95% CI of the groups of spasm at
the site of organic stenosis, with spasm at other sites/
spasm without stenosis as the reference. A 2-tailed
FIGURE 1 Study Flow
Patients underwent
ACh-provocation test
n = 1,877 (male/female: 966/911)
Acute myocardial infarction (n = 20)
Cardiomyopathy (n = 75)
Brugada syndrome (n = 10)
Others (n = 12)









n = 358 (249/109)
Patients without
organic stenosis




n = 125 (85/40)
Non-spasm without
organic stenosis
n = 762 (331/431)
ACh-positive
n = 233 (164/69)
ACh-positive
n = 640 (323/317)
Spasm at site of
organic stenosis
n = 192 (137/55)
Spasm at sites other than
the site of organic stenosis
n = 41 (27/14)
Excluded n = 117 (65/52)
This chart shows enrollment criteria and ﬂow of patients as they were grouped by presence or absence of organic stenosis and acetylcholine
(ACh)-provoked coronary spasm.
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1107p value of<0.05 denoted the presence of a statistically
signiﬁcant difference. All statistical analyses were
performed with The Statistical Package for Social
Sciences software version 21.0 (IBM Corporation,
Armonk, New York).
RESULTS
ACh-provoked coronary spasm and organic stenosis
were observed in 873 and 358 of the 1,760 patientsincluded in the present analysis, respectively
(Figure 1). Among the 358 patients with signiﬁcant
atherosclerotic stenosis (stenosisþ), ACh-provoked
coronary spasm was seen in 233 patients (AChþ/
stenosisþ): 192 with spasm at the site of signiﬁcant
organic stenosis (AChþ/stenosisþ-site) and 41 with
spasm at sites other than the site of signiﬁcant stenosis
(AChþ/stenosisþ-no site). In 125 patients with organic
stenosis, ACh did not provoke spasm (ACh-/stenosisþ).
Conversely, in 1,402 patients without organic stenosis
TABLE 1 Clinical Patient Characteristics








(n ¼ 762) p Value
Age, yrs 65.0  9.6 67.9  8.7 0.006 63.4  10.6 61.3  11.6 0.001
Female 69 (29.6) 40 (32.0) 0.640 317 (49.5) 431 (56.6) 0.009
BMI $25 kg/m2 71 (31.7) 38 (32.5) 0.883 193 (31.2) 251 (34.5) 0.200
Current smoking 147 (63.4) 68 (55.3) 0.138 313 (49.0) 307 (40.7) 0.002
Diabetes mellitus 73 (31.3) 52 (41.9) 0.045 106 (16.7) 116 (15.3) 0.466
Hypertension 116 (49.8) 71 (56.8) 0.205 246 (38.4) 286 (37.7) 0.786
Dyslipidemia 121 (52.2) 63 (50.4) 0.752 285 (44.6) 274 (36.1) 0.001
Family history of IHD 44 (18.9) 17 (13.9) 0.240 101 (15.8) 67 (8.9) <0.001
Total cholesterol, mg/dl 188.2  36.0 188.2  42.8 0.986 194.4  35.5 193.5  37.1 0.657
LDL cholesterol, mg/dl 114.7  32.8 111.2  36.0 0.361 116.4  34.1 115.1  34.5 0.476
HDL cholesterol, mg/dl 48.5  14.9 49.7  14.9 0.470 54.0  16.4 52.9  17.5 0.232
Triglyceride, mg/dl 127.5  70.4 139.7  74.9 0.134 124.1  66.3 132.0  77.1 0.051
CKD (eGFR <60 ml/min/1.73 m2) 50 (24.8) 39 (33.6) 0.090 113 (20.1) 117 (17.8) 0.320
LVEF, % 70.6  10.9 71.1  12.5 0.716 71.3  10.8 73.4  9.2 <0.001
Multivessel spasm 78 (34.3) 0 (0) — 290 (45.3) 0 (0) —
Diffuse spasm 62 (26.6) 0 (0) — 300 (46.9) 0 (0) —
Values are mean  SD or n (%).
ACh ¼ acetylcholine; BMI ¼ body mass index; CKD ¼ chronic kidney disease; eGFR ¼ estimated glomerular ﬁltration rate; HDL ¼ high-density lipoprotein; IHD ¼ ischemic
heart disease; LDL ¼ low-density lipoprotein; LVEF ¼ left ventricular ejection fraction.
TABLE 2 Regression
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1108(stenosis-), ACh provoked coronary spasm in 640
(AChþ/stenosis-) and no spasm in 762 (ACh-/stenosis-).
ACh-PROVOKED SPASM IN PATIENTS WITH AND
WITHOUT ORGANIC STENOSIS. In terms of clinicalAnalyses for Differences in ACh-Provoked Spasm Between Patients
anic Stenosis
Simple Regression Analysis Multiple Regression Analysis
OR 95% CI p Value OR 95% CI p Value
tenosis
) 0.47 0.27–0.82 0.008 0.44 0.22–0.87 0.017
0.89 0.56–1.43 0.640 1.33 0.67–2.64 0.418
0.97 0.60–1.56 0.883 1.12 0.65–1.92 0.685
1.40 0.90–2.18 0.139 1.35 0.73–2.50 0.347
0.63 0.40–0.99 0.046 0.59 0.35–0.99 0.047
0.75 0.49–1.17 0.206 0.95 0.57–1.59 0.853
1.07 0.69–1.66 0.752 1.02 0.61–1.69 0.946
1.44 0.78–2.64 0.242 1.89 0.94–3.79 0.074
min/1.73 m2) 0.65 0.39–1.07 0.091 0.71 0.41–1.23 0.224
ic stenosis
) 1.50 1.09–2.06 0.012 1.47 1.03–2.08 0.032
0.75 0.61–0.93 0.009 0.88 0.65–1.18 0.387
0.86 0.69–1.08 0.200 0.92 0.71–1.19 0.531
1.40 1.13–1.73 0.002 1.24 0.92–1.67 0.158
1.11 0.84–1.48 0.466 0.90 0.66–1.24 0.528
1.03 0.83–1.28 0.786 1.00 0.78–1.28 0.981
1.43 1.15–1.77 0.001 1.63 1.28–2.08 <0.001
1.93 1.39–2.68 <0.001 1.94 1.34–2.82 <0.001
min/1.73 m2) 1.16 0.87–1.54 0.320 1.06 0.78–1.44 0.718
R ¼ odds ratio; other abbreviations as in Table 1.characteristics (Table 1), patients with spasm and
signiﬁcant stenosis (AChþ/stenosisþ) tended to be
younger and less likely to have diabetes compared
with the ACh-/stenosisþ group, whereas the AChþ/
stenosis- group tended to be older male current
smokers who were more likely to have dyslipidemia,
a family history of IHD, and lower left ventricular
ejection fraction, compared with the ACh-/stenosis-
group.
According to regression analyses of the data
(Table 2), simple logistic regression analysis demon-
strated that age $75 years (odds ratio [OR]: 0.47;
95% CI: 0.27 to 0.82; p ¼ 0.008) and diabetes mellitus
(OR: 0.63; 95% CI: 0.40 to 0.99; p ¼ 0.046) correlated
signiﬁcantly with ACh-provoked coronary spasm in
the stenosisþ group. Multiple logistic regression
analysis also identiﬁed old age (OR: 0.44; 95% CI: 0.22
to 0.87; p ¼ 0.017) and diabetes mellitus (OR: 0.59;
95% CI: 0.35 to 0.99; p ¼ 0.047) as signiﬁcant pre-
dictors of ACh-provoked coronary spasm.
Alternatively, in the stenosis- group, simple logis-
tic regression analysis demonstrated that old age
(OR: 1.50; 95% CI: 1.09 to 2.06; p ¼ 0.012), female sex
(OR: 0.75; 95% CI: 0.61 to 0.93; p ¼ 0.009), current
smoking (OR: 1.40; 95% CI: 1.13 to 1.73; p ¼ 0.002),
dyslipidemia (OR: 1.43; 95% CI: 1.15 to 1.77; p ¼ 0.001),
and family history of IHD (OR: 1.93; 95% CI: 1.39
to 2.68; p < 0.001) all correlated signiﬁcantly with
ACh-provoked coronary spasm. In the multiple lo-
gistic regression analysis, old age (OR: 1.47; 95% CI:
TABLE 3 Clinical and Angiographic Characteristics of VSA Patients With and Without Organic Stenosis
Spasm With Organic Stenosis
Spasm Without
Organic Stenosis




At Sites Other Than
Site of Organic Stenosis
(n ¼ 41) p Value
Total
(n ¼ 233)
Age, yrs 65.1  9.5 64.6  10.1 0.768 65.0  9.6 63.4  10.6 0.045
Female 55 (28.6) 14 (34.1) 0.484 69 (29.6) 317 (49.5) <0.001
BMI $25 kg/m2 60 (32.1) 11 (29.7) 0.778 71 (31.7) 193 (31.2) 0.897
Current smoking 119 (62.3) 28 (68.3) 0.470 147 (63.4) 313 (49.0) <0.001
Diabetes mellitus 61 (31.8) 12 (29.3) 0.754 73 (31.3) 106 (16.7) <0.001
Hypertension 95 (49.5) 21 (51.2) 0.840 116 (49.8) 246 (38.4) 0.003
Dyslipidemia 97 (50.8) 24 (58.5) 0.367 121 (52.2) 285 (44.6) 0.048
Family history of IHD 39 (20.3) 5 (12.2) 0.228 44 (18.9) 101 (15.8) 0.284
Total cholesterol, mg/dl 189  36 187  34 0.783 188  36 194  35 0.029
LDL cholesterol, mg/dl 116  33 109  30 0.258 115  33 116  34 0.504
HDL cholesterol, mg/dl 48  14 52  18 0.167 48  15 54  16 <0.001
Triglyceride, mg/dl 128  67 125  84 0.824 128  70 124  66 0.521
CKD (eGFR <60 ml/min/1.73 m2) 46 (27.1) 4 (12.5) 0.080 50 (24.8) 113 (20.1) 0.163
LVEF, % 70.4  10.7 71.3  12.2 0.679 70.5  10.9 71.3  10.8 0.380
Clinical status of angina attack
At rest only 105 (54.7) 19 (46.3) 0.331 124 (53.2) 436 (68.1) <0.001
Rest and effort 25 (13.0) 6 (14.6) 0.782 31 (13.3) 52 (8.1) 0.021
ST-segment change during angina attack
ST-segment elevation 35 (18.2) 2 (4.9) 0.034 37 (15.9) 52 (8.1) 0.001
Angiographic characteristics
RCA organic stenosis 67 (34.9) 19 (46.3) 0.168 86 (36.9) — —
LAD organic stenosis 151 (78.6) 12 (29.3) <0.001* 163 (70.0) — —
LCX organic stenosis 74 (38.5) 16 (39.0) 0.954 90 (38.6) — —
RCA spasm 84 (45.2) 14 (35.9) 0.289 98 (43.6) 321 (51.5) 0.040
LAD spasm 153 (80.1) 25 (61.0) 0.009* 178 (76.7) 514 (80.3) 0.247
LCX spasm 53 (27.6) 7 (17.1) 0.162 60 (25.8) 189 (29.6) 0.268
Multivessel spasm 75 (39.1) 5 (12.2) 0.001* 80 (34.3) 290 (45.3) 0.004
Diffuse spasm 52 (27.1) 10 (24.4) 0.723 62 (26.6) 300 (46.9) <0.001
ST-segment elevation in ACh test 53 (27.6) 9 (22.0) 0.457 62 (26.6) 217 (33.9) 0.041
Medications
CCB 187 (97.4) 39 (95.1) 0.357 226 (97.0) 593 (92.7) 0.019
ACE inhibitor 26 (13.5) 6 (14.6) 0.854 32 (13.7) 64 (10.0) 0.122
ARB 20 (10.4) 6 (14.6) 0.295 26 (11.2) 55 (8.6) 0.254
Nitrates 55 (28.6) 11 (26.8) 0.815 66 (28.3) 107 (16.8) <0.001
Nicorandil 17 (8.9) 3 (7.3) 0.518 20 (8.6) 37 (5.8) 0.141
Beta-blockers 18 (9.4) 3 (7.3) 0.475 21 (9.0) 33 (5.2) 0.037
Statins 72 (37.5) 15 (36.6) 0.912 87 (37.3) 168 (26.3) 0.002
Aspirin 141 (73.4) 31 (75.6) 0.774 172 (73.8) 136 (21.3) <0.001
Values are mean  SD or n (%). *Adjusted p < 0.05; signiﬁcance probability was adjusted for Bonferroni method across the categories in subgroup analysis of the spasm
patients with organic stenosis.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin II receptor blocker; CCB ¼ calcium-channel blocker; LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex
artery; RCA ¼ right coronary artery; VSA ¼ vasospastic angina; other abbreviations as in Table 1.
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11091.03 to 2.08; p ¼ 0.032), dyslipidemia (OR: 1.63;
95% CI: 1.28 to 2.08; p < 0.001), and family history of
IHD (OR: 1.94; 95% CI: 1.34 to 2.82; p < 0.001) con-
tinued to be signiﬁcant predictors of ACh-provoked
coronary spasm (Table 2).
When compared with patients in the AChþ/
stenosis- group, those in the AChþ/stenosisþ group
were signiﬁcantly older, males, current smokers,had diabetes, hypertensive, and had dyslipidemia
(Table 3). Furthermore, these AChþ/stenosisþ patients
tended to develop both rest and effort angina with
ST-segment elevation on 12-lead electrocardiogram,
compared with those in the AChþ/stenosis- group.
Right coronary artery spasm, multivessel spasm,
diffuse spasm, and ST-segment elevation during ACh-
provocation test were more common in VSA patients



















0 12 24 36 48 60
Number at risk
Follow-Up Period (Months)
Spasm at site of organic stenosis
192 170 159 148 131 122
Spasm at sites other than the site of organic stenosis
41 38 35 29 24 21
Spasm without organic stenosis




P = 0.001(Log Rank)
Spasm at site of organic stenosis (n = 192)
Spasm at sites other than the site of organic stenosis (n = 41)
Spasm without organic stenosis (n = 640)
Kaplan-Meier survival curve shows worse 5-year survival rates free from MACE in patients with spasm at site of organic stenosis (n ¼ 192)
compared with those with spasm at sites other than the site of organic stenosis (n ¼ 41) and those with spasm but without organic stenosis
(n ¼ 640). MACE ¼ major adverse cardiac event(s).
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1110of the AChþ/stenosis- group than the AChþ/stenosisþ
group. Subgroup analysis according to the site of
spasm during ACh testing showed that patients of the
AChþ/stenosisþ-site group were more likely to expe-
rience angina with ST-segment elevation compared
with the AChþ/stenosisþ–no site group, for whom
signiﬁcant organic stenosis, spasm in the LAD, and
multivessel spasm were less common than in the
AChþ/stenosisþ-site group.
PREDICTORS OF MACE AND ACh-PROVOKED
SPASM. During a mean follow-up period of 49  19
months, 43 patients exhibited the primary endpoint,
including cardiac death in 3, hospitalization for AMI
in 6, and unstable angina in 34. Noncardiac deaths
were recorded in 27 patients. Five-year survival free
from MACE and all-cause death were 94.2% and
96.4%, respectively. Kaplan-Meier survival curves
indicated worse 5-year survival rates free from
MACE in patients of the AChþ/stenosisþ-site group
compared with those of the AChþ/stenosisþ–no
site group and those of the AChþ/stenosis- group
(p ¼ 0.048, p ¼ 0.001, respectively) (Figure 2). Uni-
variate Cox hazard analysis showed that currentsmoking, ACh-provoked spasm at the site of organic
stenosis, ST-segment elevation during an angina
attack, diffuse spasm subtype, and use of nitrates
were signiﬁcantly associated with MACE (Table 4).
Multivariate Cox hazards regression analysis identi-
ﬁed ACh-provoked spasm at the site of signiﬁcant
organic stenosis (HR: 2.28; 95% CI: 1.22 to 4.25;
p ¼ 0.010) and use of nitrates (HR: 1.94; 95% CI: 1.02
to 3.67; p ¼ 0.043) as signiﬁcant correlates of MACE in
VSA patients (Table 4).
Additionally, simple logistic regression analysis
demonstrated that ST-segment elevation during
angina, LAD organic stenosis, LAD spasm, and
multivessel spasm were closely associated with ACh-
provoked spasm at the site of signiﬁcant atheroscle-
rotic stenosis (Table 5). Furthermore, multiple logistic
regression analysis identiﬁed ST-segment elevation
during angina (OR: 5.41; 95% CI: 1.06 to 27.6;
p ¼ 0.042), LAD organic stenosis (OR: 11.0; 95% CI:
4.77 to 25.5; p <0.001), and multivessel spasm (OR:
6.21; 95% CI: 2.07 to 18.6; p ¼ 0.001) as signiﬁcant
predictors of ACh-provoked spasm at the site of
signiﬁcant organic stenosis.
TABLE 4 Univariate and Multivariate Cox Proportional Hazards Analyses for
Correlated Factors of MACE During Follow-Up
Univariate Analysis Multivariate Analysis
HR 95% CI p Value HR 95% CI p Value
Elderly (age $75 yrs) 0.62 0.22–1.74 0.366
Female 0.56 0.30–1.06 0.075 Not selected*
BMI $25 kg/m2 0.60 0.28–1.25 0.169
Current smoking 2.10 1.11–3.97 0.023 1.71 0.89–3.26 0.107
Diabetes mellitus 0.90 0.42–1.95 0.793
Hypertension 1.12 0.62–2.05 0.703
Dyslipidemia 0.96 0.53–1.74 0.884
Family history of IHD 0.81 0.34–1.91 0.628
CKD (eGFR <60 ml/min/1.73 m2) 1.12 0.53–2.37 0.767
LV dysfunction (EF <50%) 1.17 0.28–4.83 0.831
Spasm at the site of organic
stenosis
2.94 1.61–5.37 <0.001 2.51 1.37–4.63 0.003
ST-segment elevation during
angina attack
2.42 1.16–5.05 0.018 Not selected*
At rest only 2.00 0.96–4.18 0.064
RCA spasm 1.17 0.62–2.20 0.621
LAD spasm 1.28 0.57–2.87 0.551
LCX spasm 0.98 0.50–1.92 0.953
Multivessel spasm 1.24 0.68–2.25 0.482
Diffuse spasm 0.45 0.23–0.89 0.023 Not selected*
CCB 0.98 0.30–3.17 0.975
ACE inhibitor 1.58 0.71–3.56 0.266
ARB 0.48 0.12–1.98 0.310
Nitrates 2.62 1.41–4.86 0.002 2.12 1.13–3.98 0.019
Nicorandil 0.75 0.18–3.09 0.688
Beta-blockers 2.31 0.91–5.88 0.079
Statins 0.82 0.41–1.62 0.559
Aspirin 1.83 1.01–3.33 0.048 Not selected†
*This variable was not selected by the stepwise backward selection entry method. †A signiﬁcant positive
correlation was observed between aspirin and organic stenosis. Pearson correlation coefﬁcient (r) ¼ 0.486.
HR ¼ hazard ratio; MACE ¼ major adverse cardiac event(s); other abbreviations as in Tables 1 to 3.
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The major ﬁndings in this study were as follows:
1) certain coronary risk factors (old age and diabetes
mellitus) correlated negatively with ACh-provoked
coronary spasm in VSA patients with signiﬁcant
atherosclerotic stenosis, whereas coronary risk fac-
tors (old age, dyslipidemia, and family history of IHD)
correlated positively with ACh-provoked coronary
spasm in those without such stenosis; 2) ACh-
provoked coronary spasm at the site of signiﬁcant
organic stenosis and use of nitrates correlated
signiﬁcantly with the prognosis of VSA patients; and
3) ST-segment elevation during angina, LAD organic
stenosis, and multivessel spasm correlated closely
with coronary spasm at the site of organic stenosis
induced by ACh in VSA patients with organic stenosis.
To the best of our knowledge, this is the ﬁrst large
population study to investigate the contributing fac-
tors and long-term outcome in VSA Japanese patients
with and without signiﬁcant stenosis, and to deﬁne
the relationship between ACh-provoked coronary
spasm at different sites to atherosclerotic stenosis
and prognosis.
We showed a high frequency of ACh-provoked
coronary spasm (49.6%), probably reﬂecting the
high incidence of VSA in Japan compared with
Western countries (13–16). For example, in 2 U.S.
studies, the WISE (Women’s Ischemia Syndrome
Evaluation) study reported that only 2.3% to 5% of
women with angina and evidence of myocardial
ischemia who underwent invasive coronary reactivity
testing were diagnosed with coronary vasospasm
(13,14), whereas the CRUSADE (Can Rapid Risk Strat-
iﬁcation of Unstable Angina Patients Suppress
Adverse Outcomes with Early Implementation of the
American College of Cardiology/American Heart As-
sociation Guidelines) registry reported that non-
obstructive CAD was diagnosed in only 10% of
patients with non–ST-segment elevation acute coro-
nary syndrome (15.1% of women and 6.8% of men)
who underwent coronary angiography (15). Further-
more, a meta-analysis indicated that nonobstructive
coronary disease was present in only 1.6% of white
patients with ST-segment elevation myocardial
infarction (17). However, the ACOVA (Abnormal Cor-
onary Vasomotion in Patients with Stable Angina and
Unobstructed Coronary Arteries) study reported that
62% of patients with stable angina and unobstructed
CAD who had exercise-related anginal symptoms had
positive ACh-provocation tests (45% epicardial and
55% microvascular spasm), and that patients with
evidence of abnormal coronary vasomotion were
more likely to be female (18). Yet another studyreported epicardial and microvascular coronary
spasm in 57.6% of white patients with unobstructed
coronary arteries (19). Although it is not true for all
studies, it is possible that differences in inclusion
criteria, protocol of the ACh-provocation test, race,
and diagnosis of functional abnormalities of the cor-
onary arteries could explain the different incidence of
epicardial dysfunction between the present study and
previous studies.
Following multiple regression analysis, we identi-
ﬁed old age and presence of diabetes mellitus as
signiﬁcant negative predictors of ACh-provoked
spasm in patients with organic stenosis, whereas
old age, dyslipidemia, and family history of IHD were
signiﬁcant predictors of ACh-provoked spasm in pa-
tients without such stenosis. These results suggest
that coronary spasm is likely to occur at the site of
early stages of atherosclerosis, but is less likely to
occur at the site of advanced atherosclerosis, typi-
cally characterized by heavy calciﬁcation, such as in
TABLE 5 Regression Analyses for ACh-Provoked Spasm at Site of Organic Stenosis
Simple Regression Analysis Multiple Regression Analysis
OR 95% CI p Value OR 95% CI p Value
Elderly (age $75 yrs) 0.68 0.27–1.71 0.415
Female 0.77 0.38–1.59 0.484
BMI $25 kg/m2 1.12 0.52–2.41 0.778
Current smoking 0.77 0.37–1.58 0.471
Diabetes mellitus 1.13 0.54–2.35 0.754
Hypertension 0.93 0.48–1.83 0.840
Dyslipidemia 0.73 0.37–1.45 0.368
Family history of IHD 1.84 0.68–4.99 0.234
CKD (eGFR <60 ml/min/1.73 m2) 2.60 0.86–7.81 0.089
ST-segment elevation during
angina attack
4.35 1.00–18.86 0.050 5.41 1.06–27.61 0.042
RCA organic stenosis 0.62 0.31–1.23 0.170
LAD organic stenosis 8.90 4.18–18.96 <0.001 11.03 4.77–25.51 <0.001
LCX organic stenosis 0.98 0.49–1.96 0.954
RCA spasm 1.47 0.72–3.01 0.291
LAD spasm 2.58 1.25–5.30 0.010 1.23 0.51–2.99 0.650
LCX spasm 1.85 0.77–4.43 0.166
Multivessel spasm 4.62 1.73–12.29 0.002 6.21 2.07–18.66 0.001
Diffuse spasm 1.15 0.53–2.51 0.723
Abbreviations as in Tables 1 to 3.
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port to the ﬁndings of several intravascular ultra-
sound studies (20–23). Yamagishi et al. (20) reported
that even in the absence of organic stenosis on cor-
onary angiography, atherosclerosis was present at the
site of focal spasm. Furthermore, other studies indi-
cated that coronary plaque at the site of spasm rep-
resented early stages of atherosclerosis and was
characterized by minimum calciﬁcation, low echoic
plaque, and diffusely thickened ﬁbrous-dominant
plaque (21–23). However, there is no information on
the features of coronary plaque components at the
site of spasm in VSA patients with angiographically
signiﬁcant atherosclerotic stenosis. Further studies
are needed to clarify plaque morphology in such
patients.
We identiﬁed ACh-provoked spasm at the site of
signiﬁcant organic stenosis and use of nitrates as the
2 prognostic factors for MACE. Several studies
have demonstrated that the presence of organic ste-
nosis is a signiﬁcant prognostic factor in VSA patients
(24,25), although these studies did not discuss the
positional relation of coronary spasm to atheroscle-
rotic stenosis. Nishizawa et al. (26) reported that in-
termediate ﬁxed coronary stenosis at the site of
spasm induced by ergonovine was an independent
risk factor for MACE in VSA patients. However, their
study did not compare patients with coronary spasm
occurring at sites other than the site of signiﬁcantstenosis with those with coronary spasm but without
stenosis. In our study, the Kaplan-Meier survival
curve showed worse rates of 5-year survival free from
MACE in patients of the AChþ/stenosisþ-site group
compared with VSA patients of the AChþ/stenosisþ–
no site group (p ¼ 0.048), indicating that coronary
spasm is associated with the cause of the event when
the spasm occurs at the site of organic stenosis. For
this reason, calcium channel blockers are essential
for the treatment of patients with such spasm, in
addition to antianginal and antiatherosclerotic
agents, such as nitrates, antiplatelets, beta-blockers,
and statins (Central Illustration). Furthermore, we
recommend performing ACh-provocation testing in
those subjects in whom the cause of chest pain
(mainly at rest) could not be explained by the pres-
ence of signiﬁcant organic stenosis.
Based on the Kaplan-Meier survival curve, our data
suggest equal 5-year survival rates free from MACE in
patients of the AChþ/stenosisþ–no site group and the
VSA patients of the stenosis- group (p ¼ 0.235).
Interestingly, patients of the AChþ/stenosisþ–no site
group had better prognosis for MACE despite the
presence of signiﬁcant stenosis, although ACh-
provoked spasm at the site of organic stenosis was a
signiﬁcant correlate for MACE. There is no informa-
tion on the factors that contribute to ACh-provoked
coronary spasm at the site of organic stenosis. Our
study identiﬁed ST-segment elevation during angina,
stenosis of the LAD artery, and multivessel spasm as
such contributing factors.
Nitrate use was a signiﬁcant factor for poor prog-
nosis and MACE in this study. Nitrates are one of the
most widely used drugs and acutely improve cardiac
status, such as stable effort angina, unstable angina,
AMI, chronic heart failure, and VSA (27,28). However,
the long-term effects of these agents on prognosis
and the development of nitrate tolerance remain
unclear. In this regard, Kosugi et al. (29) reported that
long-term treatment with nitrate combined with cal-
cium channel blockers was an independent predictor
of cardiac events in VSA patients. Another recent
study demonstrated that long-term nitrate therapy
did not improve the prognosis of VSA patients and
that using a combination of nitrates increased the risk
of cardiac events in these patients (30). However,
these results are from nonrandomized observational
studies; accordingly, they need to be conﬁrmed in
large randomized prospective studies before one can
establish a true cause-effect relationship between use
of nitrates and prognosis.
STUDY LIMITATIONS. First, it was an observational
retrospective study. Thus, we could not fully assess
CENTRAL ILLUSTRATION Diagnostic, Prognostic, and Pharmacotherapeutic Approaches to Spasm at Site of Stenosis
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For patients with known coronary stenosis of otherwise uncertain physiological signiﬁcance who are considered for revascularization, the acetylcholine-provocation test
provides for a full assessment of the site and mode of coronary spasm. Severity of spasm helps guide optimal pharmacotherapy. MACE ¼major adverse cardiac event(s).
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Provocation of vasospasm by intracoronary ACh
administration in zones of hemodynamically signiﬁ-
cant ﬁxed stenosis is associated with a high risk of
clinical ischemic events.
TRANSLATIONAL OUTLOOK: Future studies
should explore whether speciﬁc therapeutic inter-
ventions in symptomatic patients with ACh-induced
coronary vasospasm can improve clinical outcomes.
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ment and pathological condition. Second, no sufﬁ-
cient prognostic data were available for the patients
of the nonspasm groups because, as an observational
retrospective study, these patients did not visit the
hospital regularly for medical treatment. However,
follow-up of the nonspasm group is clinically impor-
tant to determine the prognosis and need for any
medical treatment. Finally, the precision of the esti-
mate of prognostic factors might have been limited
because the absolute number of events of interest
was low. Consequently, a larger randomized multi-
center study should be conducted to conﬁrm our
results.
CONCLUSIONS
This study demonstrated the clinical features, pre-
dictive factors, and prognosis of patients with
coronary spasm at the site of signiﬁcant organic
stenosis. The present results indicated that
ACh-provoked coronary spasm at the site of sig-
niﬁcant organic stenosis was a signiﬁcant predictor
for MACE. The ﬁnding emphasizes the need to iden-
tify the site of coronary spasm in patients with sig-
niﬁcant organic stenosis so as to provide optimal
therapy for VSA patients with atherosclerotic disease.ACKNOWLEDGMENTS The authors thank Megumi
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